Fmr LLC Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Fmr LLC boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 64.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 5,572,545 shares of the medical equipment provider’s stock after acquiring an additional 2,174,093 shares during the period. Fmr LLC’s holdings in Hologic were worth $453,940,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of HOLX. Janus Henderson Group PLC lifted its position in Hologic by 29.5% during the first quarter. Janus Henderson Group PLC now owns 99,707 shares of the medical equipment provider’s stock valued at $7,773,000 after purchasing an additional 22,732 shares during the period. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Hologic by 13.0% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,198 shares of the medical equipment provider’s stock valued at $249,000 after buying an additional 367 shares during the period. Tidal Investments LLC boosted its stake in shares of Hologic by 10.8% in the 1st quarter. Tidal Investments LLC now owns 16,901 shares of the medical equipment provider’s stock worth $1,317,000 after buying an additional 1,654 shares during the last quarter. Comerica Bank grew its holdings in shares of Hologic by 40.9% in the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock worth $8,580,000 after acquiring an additional 31,967 shares during the period. Finally, iA Global Asset Management Inc. bought a new stake in shares of Hologic in the first quarter worth $37,000. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on HOLX shares. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Raymond James lifted their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada raised their target price on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, October 15th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Up 0.1 %

NASDAQ HOLX opened at $79.50 on Friday. Hologic, Inc. has a 12 month low of $67.59 and a 12 month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock has a market cap of $18.47 billion, a PE ratio of 23.87, a P/E/G ratio of 2.50 and a beta of 0.98. The stock’s 50 day moving average is $80.22 and its 200 day moving average is $78.42.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.89 earnings per share. Research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.